尼拉帕利维持治疗在复发性卵巢癌末次铂类化疗部分缓解后的应用:ENGOT-OV16/NOVA试验
ENGOT-OV16/NOVA试验纳入553例铂敏感复发性卵巢癌患者,按胚系BRCA突变状态和末次铂类化疗反应(部分缓解PR或完全缓解CR)分组进行事后分析。结果显示,无论gBRCAmut状态及末次铂类反应如何,尼拉帕利较安慰剂均改善无进展生存期,且患者报告结局无有意义差异。
要点
- 尼拉帕利维持治疗在gBRCAmut和non-gBRCAmut队列的PR和CR亚组中均改善PFS。
- non-gBRCAmut队列PR亚组HR 0.35,CR亚组HR 0.58,均具统计学意义。
核心结论
- 无论患者对末次铂类化疗是部分缓解还是完全缓解,尼拉帕利维持治疗均带来临床获益。
研究设计与样本
- ENGOT-OV16/NOVA试验共纳入553例铂敏感复发性卵巢癌患者,按gBRCAmut状态和末次铂类反应进行事后分析。
- gBRCAmut队列203例(PR 99例,CR 104例),non-gBRCAmut队列350例(PR 173例,CR 177例)。
- 评估安全性、进展风险及卵巢癌特异性症状和生活质量(FACT-O Symptom Index)。
主要发现
- 任何级别及3级及以上不良事件发生率可控。
- PR和CR亚组中,尼拉帕利与安慰剂在患者报告结局方面无有意义差异。
临床怎么用
- 对于铂敏感复发性卵巢癌患者,无论末次铂类化疗后达到PR还是CR,均可考虑尼拉帕利维持治疗。
局限性
- 本研究为事后分析,结果需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: In the ENGOT-OV16/NOVA trial (ClinicalTrials.gov identifier: NCT01847274), maintenance therapy with niraparib, a poly(ADP-ribose) polymerase inhibitor, prolonged progression-free survival in patients with platinum-sensitive, recurrent ovarian cancer who had a response to their last platinum-based chemotherapy. The objective of the study was to assess the clinical benefit and patient-reported outcomes in patients who had a partial response (PR) and complete response (CR) to their last platinum-based therapy. PATIENTS AND METHODS: A total of 553 patients were enrolled in the trial. Of 203 patients with a germline BRCA mutation (gBRCAmut), 99 had a PR and 104 had a CR to their last platinum-based therapy; of 350 patients without a confirmed gBRCAmut (non-gBRCAmut), 173 had a PR and 177 had a CR. Post hoc analyses were carried out to evaluate safety and the risk of progression in these patients according to gBRCAmut status and response to their last platinum-based therapy. Ovarian cancer-specific symptoms and quality of life were assessed using the Functional Assessment of Cancer Therapy-Ovarian Symptom Index. RESULTS: Progression-free survival was improved in patients treated with niraparib compared with placebo in both the gBRCAmut cohort (PR: hazard ratio [HR], 0.24; 95% CI, 0.131 to 0.441; P < .0001; CR: HR, 0.30; 95% CI, 0.160 to 0.546; P < .0001) and the non-gBRCAmut cohort (PR: HR, 0.35; 95% CI, 0.230 to 0.532; P < .0001; CR: HR, 0.58; 95% CI, 0.383 to 0.868; P = .0082). The incidence of any-grade and grade 3 or greater adverse events was manageable. No meaningful differences were observed between niraparib and placebo in PR and CR subgroups with respect to patient-reported outcomes. CONCLUSION: Patients achieved clinical benefit from maintenance treatment with niraparib regardless of response to the last platinum-based therapy.
引用
- Del Campo JM, Matulonis UA, Malander S, et al. Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial. J Clin Oncol. 2019. PMID: 31173551. doi:10.1200/JCO.18.02238
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。